Literature DB >> 33536186

Uveitis for the non-ophthalmologist.

Bryn M Burkholder1, Douglas A Jabs2,3.   

Abstract

The uveitides are a heterogeneous group of diseases characterized by inflammation inside the eye. The uveitides are classified as infectious or non-infectious. The non-infectious uveitides, which are presumed to be immune mediated, can be further divided into those that are associated with a known systemic disease and those that are eye limited,-ie, not associated with a systemic disease. The ophthalmologist identifies the specific uveitic entity by medical history, clinical examination, and ocular imaging, as well as supplemental laboratory testing, if indicated. Treatment of the infectious uveitides is tailored to the particular infectious organism and may include regional and/or systemic medication. First line treatment for non-infectious uveitides is corticosteroids that can be administered topically, as regional injections or surgical implants, or systemically. Systemic immunosuppressive therapy is used in patients with severe disease who cannot tolerate corticosteroids, require chronic corticosteroids at >7.5 mg/day prednisone, or in whom the disease is known to respond better to immunosuppression. Management of many of these diseases is optimized by coordination between the ophthalmologist and rheumatologist or internist. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Year:  2021        PMID: 33536186     DOI: 10.1136/bmj.m4979

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  9 in total

Review 1.  Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases.

Authors:  Meini Chen; Rong Rong; Xiaobo Xia
Journal:  J Neuroinflammation       Date:  2022-07-14       Impact factor: 9.587

2.  A Novel Tree Shrew Model of Chronic Experimental Autoimmune Uveitis and Its Disruptive Application.

Authors:  Kaijiao Hu; Longbao Lv; Hui Huang; Guangnian Yin; Jie Gao; Jianping Liu; Yaying Yang; Wenxin Zeng; Yan Chen; Ni Zhang; Feiyan Zhang; Yuhua Ma; Feilan Chen
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

3.  "Listen to Your Immune System When It's Calling for You": Monitoring Autoimmune Diseases Using the iShU App.

Authors:  Cláudia Ortet; Liliana Vale Costa
Journal:  Sensors (Basel)       Date:  2022-05-18       Impact factor: 3.847

Review 4.  Immune cells in lens injury repair and fibrosis.

Authors:  Janice L Walker; A Sue Menko
Journal:  Exp Eye Res       Date:  2021-06-11       Impact factor: 3.770

Review 5.  Immune responses to injury and their links to eye disease.

Authors:  Mary Ann Stepp; A Sue Menko
Journal:  Transl Res       Date:  2021-05-27       Impact factor: 10.171

Review 6.  Research Progress on the Mechanism of Natural Product Ingredients in the Treatment of Uveitis.

Authors:  Sicong Li; Fang Liu; Kai Zhang; Yujia Tong; Xin Liu
Journal:  J Immunol Res       Date:  2021-07-16       Impact factor: 4.818

Review 7.  LRG1 as a novel therapeutic target in eye disease.

Authors:  Giulia De Rossi; Marlene E Da Vitoria Lobo; John Greenwood; Stephen E Moss
Journal:  Eye (Lond)       Date:  2022-01-05       Impact factor: 4.456

Review 8.  Ocular Nanomedicine.

Authors:  Zhimin Tang; Xianqun Fan; Yu Chen; Ping Gu
Journal:  Adv Sci (Weinh)       Date:  2022-02-12       Impact factor: 17.521

9.  Uveitis-mediated immune cell invasion through the extracellular matrix of the lens capsule.

Authors:  JodiRae DeDreu; Sonali Pal-Ghosh; Mary J Mattapallil; Rachel R Caspi; Mary Ann Stepp; A Sue Menko
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.